Time filter

Source Type

Messaoud O.,Pasteur Institute of Tunis | Ben Rekaya M.,Pasteur Institute of Tunis | Kefi R.,Pasteur Institute of Tunis | Chebel S.,Fattouma Bourguiba Hospital | And 8 more authors.
British Journal of Dermatology | Year: 2010

Xeroderma pigmentosum (XP) is a rare genodermatosis predisposing to skin cancers. The disease is classified into eight groups. Among them, XP group A (XP-A) is characterized by the presence of neurological abnormalities in addition to cutaneous symptoms. In the present study, we report a particular family with XP-A in which some members showed an atypical clinical presentation, i.e. unexplained neurological abnormalities with discrete skin manifestations. Molecular investigation allowed identification of a novel XPA mutation and complete phenotype-genotype correlation for this new phenotypic expression of XP-A. © 2010 British Association of Dermatologists.

Messaoud O.,Pasteur Institute of Tunis | Ben Rekaya M.,Pasteur Institute of Tunis | Ouragini H.,Pasteur Institute of Tunis | Benfadhel S.,Pasteur Institute of Tunis | And 8 more authors.
Archives of Dermatological Research | Year: 2012

Xeroderma pigmentosum (XP) is a rare disorder characterized by a high skin sun-sensitivity predisposing to skin cancers at an early age. Among Tunisian XP patients with an intermediate skin phenotype, 92% presented neurological abnormalities related to XPA gene deficiency. Clinical variability of the XP-A phenotype is associated with a mutational heterogeneity. In the present study, two Tunisian families with severe dermatological and neurological XP phenotypes were investigated in order to determine clinical characteristics and genetic basis. Two Tunisian families with four XP affected children were examined in the Dermatology Department. Clinical features showed severe presentation of the disease. Coding regions of the XPA gene were analysed by direct sequencing. Results showed the presence of a novel mutation, p.E111X, in three patients belonging to the same family and presenting a very severe phenotype i.e. development of skin lesions and neurological signs before 1 year age. For the other patient, we identified a nonsense mutation, p.R207X, already identified in a Palestinian XP-A patient. Identification of novel causing mutations in Tunisian XP-A patients shows the genetic and mutational heterogeneity of the disease in Tunisia. Despite a relatively homogenous mutational spectrum, mutational heterogeneity for rare cases is observed because of the high rate of consanguinity. © 2011 Springer-Verlag.

Loading Neurology Institute of Tunis collaborators
Loading Neurology Institute of Tunis collaborators